Tsolaki Vasiliki, Zakynthinos George E, Karavidas Nikitas, Vazgiourakis Vasileios, Papanikolaou John, Parisi Kyriaki, Zygoulis Paris, Makris Demosthenes, Zakynthinos Epaminondas
Critical Care Department, Faculty of Medicine, University Hospital of Larissa, University of Thessaly, Mezourlo, 41110, Larissa, Greece.
Third Cardiology Clinic, University of Athens, Sotiria Hospital, Athens, Greece.
Ann Intensive Care. 2024 Feb 12;14(1):25. doi: 10.1186/s13613-024-01241-1.
Cardiac injury is frequently reported in COVID-19 patients, the right ventricle (RV) is mostly affected. We systematically evaluated the cardiac function and longitudinal changes in severe COVID-19 acute respiratory distress syndrome (ARDS) admitted to the intensive care unit (ICU) and assessed the impact on survival.
We prospectively performed comprehensive echocardiographic analysis on mechanically ventilated COVID-19 ARDS patients, using 2D/3D echocardiography. We defined left ventricular (LV) systolic dysfunction as ejection fraction (EF) < 40%, or longitudinal strain (LS) > - 18% and right ventricular (RV) dysfunction if two indices among fractional area change (FAC) < 35%, tricuspid annulus systolic plane excursion (TAPSE) < 1.6 cm, RV EF < 44%, RV-LS > - 20% were present. RV afterload was assessed from pulmonary artery systolic pressure (PASP), PASP/Velocity Time Integral in the right ventricular outflow tract (VTI) and pulmonary acceleration time (PAcT). TAPSE/PASP assessed the right ventriculoarterial coupling (VAC).
Among 176 patients included, RV dysfunction was common (69%) (RV-EF 41.1 ± 1.3%; RV-FAC 36.6 ± 0.9%, TAPSE 20.4 ± 0.4mm, RV-LS:- 14.4 ± 0.4%), usually accompanied by RV dilatation (RVEDA/LVEDA 0.82 ± 0.02). RV afterload was increased in most of the patients (PASP 33 ± 1.1 mmHg, PAcT 65.3 ± 1.5 ms, PASP/VTI, 2.29 ± 0.1 mmHg/cm). VAC was 0.8 ± 0.06 mm/mmHg. LV-EF < 40% was present in 21/176 (11.9%); mean LV-EF 57.8 ± 1.1%. LV-LS (- 13.3 ± 0.3%) revealed a silent LV impairment in 87.5%. A mild pericardial effusion was present in 70(38%) patients, more frequently in non-survivors (p < 0.05). Survivors presented significant improvements in respiratory physiology during the 10th ICU-day (PaO/FiO, 231.2 ± 11.9 vs 120.2 ± 6.7 mmHg; PaCO, 43.1 ± 1.2 vs 53.9 ± 1.5 mmHg; respiratory system compliance-C, 42.6 ± 2.2 vs 27.8 ± 0.9 ml/cmHO, all p < 0.0001). Moreover, survivors presented significant decreases in RV afterload (PASP: 36.1 ± 2.4 to 20.1 ± 3 mmHg, p < 0.0001, PASP/VTI: 2.5 ± 1.4 to 1.1 ± 0.7, p < 0.0001 PAcT: 61 ± 2.5 to 84.7 ± 2.4 ms, p < 0.0001), associated with RV systolic function improvement (RVEF: 36.5 ± 2.9% to 46.6 ± 2.1%, p = 0.001 and RV-LS: - 13.6 ± 0.7% to - 16.7 ± 0.8%, p = 0.001). In addition, RV dilation subsided in survivors (RVEDA/LVEDA: 0.8 ± 0.05 to 0.6 ± 0.03, p = 0.001). Day-10 C correlated with RV afterload (PASP/VTI, r: 0.535, p < 0.0001) and systolic function (RV-LS, 0.345, p = 0.001). LV-LS during the 10th ICU-day, while ΔRV-LS and ΔPASP/RVOT were associated with survival.
COVID-19 improvements in RV function, RV afterload and RV-PA coupling at day 10 were associated with respiratory function and survival.
新冠病毒病(COVID-19)患者常出现心脏损伤,其中右心室(RV)受累最为常见。我们系统评估了入住重症监护病房(ICU)的重症COVID-19急性呼吸窘迫综合征(ARDS)患者的心脏功能及纵向变化,并评估了其对生存的影响。
我们对接受机械通气的COVID-19 ARDS患者前瞻性地进行了全面的超声心动图分析,采用二维/三维超声心动图。我们将左心室(LV)收缩功能障碍定义为射血分数(EF)<40%,或纵向应变(LS)>-18%;若存在以下两个指标,则定义为右心室(RV)功能障碍:面积变化分数(FAC)<35%、三尖瓣环收缩期平面位移(TAPSE)<1.6 cm、RV EF<44%、RV-LS>-20%。通过肺动脉收缩压(PASP)、右心室流出道速度时间积分(VTI)与PASP的比值以及肺动脉加速时间(PAcT)评估RV后负荷。TAPSE/PASP评估右心室-动脉耦合(VAC)。
在纳入的176例患者中,RV功能障碍很常见(69%)(RV-EF 41.1±1.3%;RV-FAC 36.6±0.9%,TAPSE 20.4±0.4mm,RV-LS:-14.4±0.4%),通常伴有RV扩张(RVEDA/LVEDA 0.82±0.02)。大多数患者的RV后负荷增加(PASP 33±1.1 mmHg,PAcT 65.3±1.5 ms,PASP/VTI 2.29±0.1 mmHg/cm)。VAC为0.8±0.06 mm/mmHg。176例患者中有21例(11.9%)出现LV-EF<40%;平均LV-EF为57.8±1.1%。LV-LS(-13.3±0.3%)显示87.5%的患者存在隐匿性LV损伤。70例(38%)患者存在轻度心包积液,在非幸存者中更常见(p<0.05)。幸存者在ICU第10天时呼吸生理有显著改善(PaO/FiO,231.2±11.9 vs 120.2±6.7 mmHg;PaCO,43.1±1.2 vs 53.9±1.5 mmHg;呼吸系统顺应性-C,42.6±2.2 vs 27.8±0.9 ml/cmH₂O,均p<0.0001)。此外,幸存者的RV后负荷显著降低(PASP:36.1±2.4至20.1±3 mmHg,p<0.0001,PASP/VTI:2.5±1.4至1.1±0.7,p<0.0001,PAcT:61±2.5至84.7±2.4 ms,p<0.0001),同时伴有RV收缩功能改善(RVEF:36.5±2.9%至46.6±2.1%,p = 0.001;RV-LS:-13.6±0.7%至-16.7±0.8%,p = 0.001)。此外,幸存者的RV扩张减轻(RVEDA/LVEDA:0.8±0.05至0.6±0.03,p = 0.001)。第10天的C与RV后负荷(PASP/VTI,r:0.535,p<0.0001)和收缩功能(RV-LS,0.345,p = 0.001)相关。ICU第10天时的LV-LS,而ΔRV-LS和ΔPASP/RVOT与生存相关。
第10天时COVID-19患者RV功能、RV后负荷及RV-PA耦合的改善与呼吸功能及生存相关。